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Summary 
Limited access to HBV DNA quantification represents a key barrier to global HBV elimination. 
We demonstrated high diagnostic accuracy of low-cost immunoassay, hepatitis B core-related 
antigen, to diagnose HBV DNA levels, and to select patients for antiviral therapy in Africa. 
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Abstract  
Background 
To eliminate hepatitis B virus (HBV) infection, it is essential to scale up testing and treatment. 
However, conventional tools to assess treatment eligibility, particularly nucleic acid testing 
(NAT) to quantify HBV DNA, are hardly available and affordable in resource-limited countries. 
We therefore assessed the performance of novel immunoassay, hepatitis B core-related antigen 
(HBcrAg), as an inexpensive (US$ <10-15/assay) alternative to NAT to diagnose clinically 
important HBV DNA thresholds (≥2,000; ≥20,000; and ≥200,000 IU/ml), and select patients for 
antiviral therapy in Africa.  
Methods 
Using well-characterized cohort of treatment-naïve patients with chronic HBV infection in The 
Gambia, we evaluated the accuracy of serum HBcrAg to diagnose HBV DNA levels, and to 
indicate treatment eligibility determined by the American Association for the Study of Liver 
Diseases, based on the reference tests (HBV DNA, HBV e antigen (HBeAg), alanine 
transaminase (ALT), liver histopathology and/or FibroScan). 
Results 
A total of 284 treatment-naïve patients were included in the analysis. The area under the receiver 
operating characteristic curve (AUROC), sensitivity and specificity of serum HBcrAg were: 0.88 
(95% CI: 0.82-0.93), 83.3% and 83.9% to diagnose HBV DNA ≥2,000 IU/ml; and 0.94 (0.88-
0.99), 91.4% and 93.2% for ≥200,000 IU/ml. A simplified treatment algorithm using HBcrAg 
without HBV DNA showed high AUROC (0.91 (95% CI: 0.88-0.95)) with a sensitivity of 96.6% 
and specificity of 85.8%.  
Conclusions 
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HBcrAg might be an accurate alternative to HBV DNA quantification as a simple and 
inexpensive tool to identify HBV-infected patients in need of antiviral therapy in low- and 
middle-income countries. 
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Hepatitis B core-related antigen; diagnostic test; validation studies; sensitivity and specificity; 
Africa 
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Introduction  
Hepatitis B Virus (HBV) infection is a major global health problem, and recognized as a public 
health priority by the UN’s Sustainable Development Goals. Subsequently, the World Health 
Organization (WHO) has developed a strategy to eliminate viral hepatitis by 2030, and one of the 
objectives is to globally increase the treatment uptake in people with chronic HBV infection 
(CHB) eligible for antiviral therapy from 8% (2015) to 80% (2030) [1]. To achieve this goal, it is 
critical to scale up screening for hepatitis B surface antigen (HBsAg), and clinical staging for 
those carrying HBsAg to assess treatment eligibility. 
 
Quantification of HBV DNA constitutes an essential element of the clinical staging. The 
international guidelines define having high viremia (≥2,000 or ≥20,000 IU/ml), in the presence of 
liver inflammation or fibrosis, to be one of the criteria to initiate antiviral therapy [2–5]. 
Moreover, the cut-off of ≥200,000 IU/ml is now used to select pregnant women for antiviral 
therapy to prevent mother-to-child transmission [2,3]. However, the vast majority (>95%) of 
HBV-infected people live in low- and middle-income countries (LMICs) [6], and they have 
severely limited access to real-time polymerase chain reaction (PCR), a molecular assay to 
measure HBV DNA levels [7]. PCR is expensive, often restricted to large urban laboratories, and 
requires highly skilled laboratory technicians. Consequently, the WHO fully acknowledges an 
urgent need for a low-cost simple assay to measure HBV replication [8].  
 
HBV core-related antigen (HBcrAg), consisting of three viral proteins (HBV core antigen, e 
antigen (HBeAg) and a small core-related protein (p22cr)), is a novel serological marker of HBV 
replication [9]. Studies in Asia and Europe confirmed a close correlation between serum HBcrAg 
levels and serum HBV DNA levels in treatment-naïve patients with CHB [10–13]. Moreover, 
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several studies also found a correlation of serum HBcrAg levels with intrahepatic covalently 
closed circular DNA (cccDNA), a transcriptional template of HBV [10,11,14,15]. Because this 
immunoassay is cheaper (US$ <10-15/assay) and simpler than the conventional real-time PCR 
(US$ 60-200/assay), this may represent an attractive alternative in LMICs. For hepatitis C virus 
(HCV) infection, a similar case has been already made. WHO now recommends the use of 
immunoassay (HCV core antigen: HCVcAg) to diagnose chronic HCV infection when HCV 
RNA PCR is not accessible [8], as HCVcAg is an accurate and inexpensive alternative to HCV 
RNA [16–18]. 
 
We assessed the performance of serum HBcrAg levels to diagnose three clinically important 
HBV DNA thresholds (2,000, 20,000, and 200,000 IU/ml) in a well-characterized cohort of 
treatment-naïve CHB patients in The Gambia, West Africa. We also evaluated the associations of 
serum HBcrAg levels with significant liver fibrosis and inflammation, and the diagnostic 
accuracy of simplified treatment algorithms using HBcrAg as an alternative to HBV DNA, to 
correctly classify those eligible for antiviral therapy according to the conventional tests (HBV 
DNA, liver histology or FibroScan) as a reference. 
 
 
Materials and Methods 
Study participants 
In 2011-2014, the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) Program 
recruited Gambian adults identified to carry HBsAg through community-based and blood bank 
screening using a rapid test (Determine, Alere, USA; or OnSite Combo Rapid Test, CTK Biotech, 
USA) [19,20]. In addition, the program also recruited symptomatic patients with chronic liver 
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disease referred from health facilities throughout the country [21]. After informed consent, 
HBsAg-positive participants systematically underwent following clinical evaluation: fasting 
transient elastography (FibroScan 402, Echosens, France) [22], abdominal ultrasonography, 
hematology and biochemistry tests, HBeAg (ETI-EBK Plus, Diasorin, Italy), and HBV DNA (in-
house real-time PCR, limit of detection: 50 IU/ml) [23]. All these laboratory analyses were 
performed locally. A subset of patients underwent liver biopsy [24]. Patients consecutively 
recruited from April 2012 to October 2013 were included in the current analysis. We excluded 
from the analysis participants with hepatocellular carcinoma (HCC), prior or current antiviral 
therapy for HBV, HIV co-infection, or missing virological data.  
 
Serum HBcrAg and HBsAg-HQ 
Patients’ sera at the recruitment were stored at -80 °C and shipped to Toshiba General hospital, 
Tokyo, Japan, where HBcrAg was quantified using a fully automated chemiluminescent 
immunoassay (CLIA) Lumipulse G600II (Fujirebio Inc, Tokyo, Japan) according to the 
manufacturer’s instructions. The assay provided a reportable range of 3-7 log U/ml. Samples with 
HBcrAg >7 log U/ml were diluted and retested to quantify HBcrAg levels. HBsAg quantification 
was also made using a highly sensitive CLIA (HBsAg-HQ) with Lumipulse (limit of detection: 
0.005 IU/ml). These measurements were performed by staff blinded to the reference test results. 
 
International treatment guidelines 
The conventional treatment criteria established by the international guidelines are summarized in 
Supplementary Table 1. The American Association for the Study of Liver Diseases (AASLD), 
European Association for the Study of the Liver (EASL), and Asian Pacific Association for the 
Study of the Liver (APASL) largely rely on three factors: levels of viral replication by HBV 
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DNA PCR and/or HBeAg sero-status, degree of liver inflammation based on liver histopathology 
and/or alanine aminotransferase (ALT) levels, and fibrosis staging by histopathology or liver 
stiffness measurement [2–4]. For these criteria, significant liver fibrosis and cirrhosis were 
defined as Metavir ≥F2 and F4 in those who had biopsy, and liver stiffness ≥7.9 kPa and ≥9.5 
kPa in those without biopsy, respectively [24]. Family history of HCC was not used to define 
treatment eligibility due to its poor ascertainment in The Gambia [25]. The WHO guidelines 
provides criteria for LMICs where HBV DNA testing is not available: cirrhosis, diagnosed by 
physical examination or aspartate aminotransferase (AST)-to-platelet ration index (APRI) >2.0; 
or persistently elevated ALT [5]. Because the cross-sectional data was used in this study, the 
eligibility was considered on a single time point. We used upper limits of normal for ALT 
specifically defined in each guidelines (Supplementary Table 2).    
 
Simplified treatment algorithms using HBcrAg 
We developed three simplified algorithms using HBcrAg (Models 1-3) to select HBsAg-positive 
patients for antiviral therapy. Model 1 is exactly same as the conventional criteria (AASLD, 
EASL and APASL) except for HBV DNA which was replaced by HBcrAg, and liver 
histopathology replaced by FibroScan. Optimal HBcrAg cut-off levels equivalent to HBV DNA 
thresholds of ≥2,000 and ≥20,000 IU/ml were applied to these conventional criteria 
(Supplementary Table 3). Model 2 is a simple score based on HBcrAg and ALT alone, which is 
similar to the Treatment Eligibility in Africa for HBV (TREAT-B) scoring system composed of 
HBeAg and ALT levels [26]. In this Model, HBcrAg levels were dichotomized into high and low 
using an optimal threshold corresponding to HBV DNA levels of ≥2,000 IU/ml. The total point 
was obtained by adding: HBcrAg score, low (0 point) or high (1); and ALT score, <20 IU/L (0 
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point), 20-39 (1), 40-79 (2) or ≥80 (3). We considered the score of ≥2 to indicate treatment 
eligibility [26]. Model 3 only used the dichotomized HBcrAg levels. 
 
Statistical analyses 
Quantified levels of serum HBV DNA, HBcrAg and HBsAg-HQ were log10 transformed, and the 
detection limit of each assay was assigned to samples with undetectable result. The correlation 
between these markers was assessed using Pearson’s correlation coefficient. The correlation was 
also evaluated by HBeAg sero-status and viral genotypes. The capability of HBcrAg levels to 
correctly discriminate clinically important HBV DNA levels at three different cut-offs (≥2,000, 
≥20,000, and ≥200,000 IU/ml) was evaluated by the receiver operating characteristic (ROC) 
curve. The optimal cut-offs for HBcrAg levels were selected to minimize the absolute difference 
between the sensitivity and specificity. The discrimination capabilities of HBcrAg levels were 
compared to those of HBsAg-HQ levels and HBeAg using area under the ROC curve (AUROC).  
 
Among the virological factors (HBcrAg/HBsAg-HQ/HBeAg/HBV DNA/genotypes), those 
associated with liver inflammation (ALT ≥40 IU/L) and significant fibrosis were identified using 
logistic regression. The factors significantly associated with the outcome in the univariable 
analyses (p<0.05) were further included in the multivariable model.  
  
The performance of the simplified algorithms using HBcrAg (Models 1-3) was evaluated for each 
of the international guidelines (AASLD/EASL/APASL) as a reference. By using the AUROC, 
the discrimination capabilities of these algorithms were compared to the WHO criteria and 
TREAT-B. All the analyses were performed using Stata 13.0 (Stata Corporation, USA). The 
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study was approved by the Gambian Government/MRC Joint Ethics Committee, and reported in 
accordance with the STARD [27].  
 
 
Results 
Study participants 
Of 372 HBsAg-positive participants assessed for serum HBcrAg, 284 were included in the 
current analysis, after excluding 74 HCC cases, 9 HIV co-infection, and 5 with missing data 
(Figure 1). Their characteristics were described in Table 1. Median age was 36 years 
(interquartile range, IQR: 30-45), and 66% were men. Positive HBeAg, HBcrAg, and HBV DNA 
were observed in 36 (13%), 152 (53%), and 165 patients (58%), respectively. Median levels of 
HBsAg-HQ, HBcrAg, and HBV DNA were 3.6 log IU/ml (IQR: 2.9-4.1), 4.0 log U/ml (3.3-5.7), 
and 2.9 log IU/ml (2.2-5.0), respectively, after excluding undetectable values. Majority harbored 
genotype E (84%), followed by A (16%). Proportion of patients eligible for antiviral therapy 
according to the AASLD, EASL, APASL, and WHO criteria for LMICs was 21%, 20%, 22%, 
and 49%, respectively.   
 
Correlation of HBcrAg with HBV DNA and HBsAg-HQ 
Correlation coefficient (r) was 0.75 (p<0.0001) between HBcrAg and HBV DNA (Figure 2). The 
positive correlation was also confirmed in a subset of patients stratified by HBeAg sero-status 
(r=0.59, p=0.0002 for HBeAg-positive; and r=0.57, p<0.0001 for HBeAg-negative), and by 
genotype (r=0.69, p<0.0001 for genotype A; and r=0.76, p<0.0001 for genotype E) 
(Supplementary Figure 1). In contrast, the correlation was poor between HBcrAg and HBsAg-
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HQ (r=0.22, p=0.0003), and between HBsAg-HQ and HBV DNA (r=0.16, p=0.006) (Figure 2), 
irrespective of HBeAg positivity or viral genotype (Supplementary Figures 2-3).  
 
Performance of HBcrAg to diagnose viral load 
AUROC of HBcrAg to diagnose clinically important HBV DNA levels were: 0.88 (95% CI: 
0.82-0.93) for ≥2,000 IU/ml; 0.92 (0.87-0.98) for ≥20,000 IU/ml; and 0.94 (0.88-0.99) for 
≥200,000 IU/ml (Table 2, Figure 3). The optimal cut-off of HBcrAg, sensitivity and specificity at 
each HBV DNA levels were: 3.6 log U/ml, 83.3% and 83.9% to diagnose viremia ≥2,000 IU/ml; 
4.8 log U/ml, 88.9% and 92.9% for ≥20,000 IU/ml; and 5.3 log U/ml, 91.4% and 93.2% for 
≥200,000 IU/ml.  
 
In contrast to HBcrAg, HBsAg-HQ was not informative; the AUROC was 0.55 (95% CI: 0.48-
0.62), 0.53 (0.45-0.61), and 0.56 (0.47-0.66), for ≥2,000, ≥20,000 and ≥200,000 IU/ml, 
respectively. AUROC of HBeAg was modest: 0.73 (95% CI: 0.66-0.79) for ≥2,000 IU/ml; 0.79 
(0.71-0.86) for ≥20,000 IU/ml; and 0.83 (0.75-0.91) for ≥200,000 IU/ml. HBcrAg performed 
significantly better than HBsAg-HQ and HBeAg for all these HBV DNA thresholds (Table 2). 
 
Association of HBcrAg with ALT and fibrosis stage 
Box plots of HBcrAg according to ALT levels and fibrosis stage showed the positive correlation 
between these variables (Supplementary Figure 4). Of the virological factors, serum HBcrAg was 
the only variable independently associated with significant fibrosis (Table 3): compared to those 
with low HBcrAg levels (<3.6 log U/ml), its risk was 2.6 times (95% CI: 1.2-5.8) higher in those 
with 3.6-5.3 log U/ml, and 19.7 times (4.3-91.1) higher in those with ≥5.3 log U/ml (adjusted 
p<0.001). Similarly, the statistically significant association with elevated ALT levels (≥40 IU/L) 
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was only observed for HBcrAg after mutually adjusting for other viral factors. No statistically 
significant association was observed in the rest (HBsAg-HQ, HBeAg, HBV DNA and genotype). 
Without any significant change in the standard errors of regression coefficients of the virological 
factors between the crude and adjusted analyses, collinearity between these was unlikely. 
 
Performance of simplified treatment algorithms using HBcrAg 
AUROC of Model 1, the algorithm using HBcrAg, HBeAg, ALT, and FibroScan, without HBV 
DNA, to select patients eligible for antiviral therapy was 0.91 (95% CI: 0.88-0.95) for AASLD, 
0.91 (0.88-0.94) for EASL, and 0.96 (0.93-0.98) for APASL (Table 4, Figure 4). AUROC of 
Model 2, the simplified score based on HBcrAg and ALT levels was 0.90 (95% CI: 0.85-0.94) 
for AASLD, 0.89 (0.84-0.94) for EASL, and 0.96 (0.94-0.98) for APASL. The AUROC did not 
significantly differ between the Model 1 and 2 across the guidelines (Supplementary Table 4). 
Model 3 which only uses HBcrAg did not perform well compared to the Model 1 and 2, with the 
AUROC varying between 0.80 and 0.84. 
 
TREAT-B, composed of ALT and HBeAg, showed AUROC of 0.87 (95% CI: 0.81-0.92) for 
AASLD, 0.87 (0.81-0.93) for EASL, and 0.95 (0.93-0.98) for APASL. Compared to TREAT-B, 
the AUROC of Model 1 was marginally higher to diagnose AASLD (p=0.09) and EASL (p=0.07), 
but no difference was observed for APASL (p=0.8, Supplementary Table 4). The AUROC of 
Model 2 was significantly higher than that of TREAT-B to indicate AASLD criteria (p=0.04, 
Supplementary Table 4); however, there was no statistically significant difference for EASL 
(p=0.2) and APASL (p=0.8). The WHO criteria discriminated poorly: the AUROCs ranged 
between 0.73 and 0.80, and were significantly lower than those of any of the algorithms 
presented, except for the Model 3 to diagnose APASL criteria. 
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Discussion 
In developed countries, HBcrAg has recently emerged as a novel tool to monitor HBV-infected 
patients under nucleos(t)ide analogues therapy [28]. Although persistence of HBV cccDNA in the 
nucleus of infected hepatocytes determines the chronicity of HBV infection and therefore 
represents a genuine marker of HBV replication, it is difficult to measure intrahepatic amount of 
cccDNA in routine clinical practice as this requires liver biopsy. Alternatively, serum HBV DNA 
is commonly used as a surrogate biomarker to evaluate HBV replication. However, its correlation 
with intrahepatic cccDNA is lost in patients treated with nucleos(t)ides analogues, because these 
drugs almost invariably lead to undetectable serum HBV DNA by blocking reverse transcription, 
while cccDNA still persists in majority of treated patients [29]. Another frequently used 
biomarker is serum HBsAg levels, but the degree of correlation with intrahepatic cccDNA is 
controversial, particularly for those negative for HBeAg, since HBsAg can be derived not only 
from cccDNA, but also from HBV DNA integrated into the host genome [30]. In contrast, serum 
HBcrAg was found to be closely correlated with the amount of intrahepatic cccDNA before 
antiviral therapy [10,11,14,15,31,32]. After the initiation of nucleos(t)ides analogues, HBcrAg 
was found to reduce to a similar extent to the reduction in cccDNA [10,11,14,31]. Moreover, the 
transcriptional activity of intrahepatic cccDNA, represented by pregenomic RNA, has been also 
shown to be correlated with serum HBcrAg levels in patients with [33] or without nucleos(t)ides 
analogues [15]. Consequently, HBcrAg is now proposed as a novel marker for treatment response 
monitoring, and also as an endpoint for clinical trials of novel HBV drugs aiming at a functional 
cure of HBV infection [15,28,34]. 
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In addition to its valuable and unique role in monitoring patients under HBV treatment, this study 
demonstrated for the first time that HBcrAg might be useful alternative to serum HBV DNA for 
the initial clinical assessment following HBsAg screening, to select patients in need of antiviral 
therapy in resource-limited settings. By comparing with serum HBV DNA PCR and treatment 
eligibility criteria centered by HBV viral load as references, we found (i) close correlation 
between HBcrAg and HBV DNA irrespective of HBeAg sero-status and HBV genotypes; (ii) 
excellent performance of HBcrAg to diagnose HBV DNA levels of ≥2,000, ≥20,000 and 
≥200,000 IU/ml; and (iii) high accuracy of simplified treatment algorithm using HBcrAg 
serology. Moreover, accumulating evidence suggest that HBcrAg may not only serve as an 
“alternative”, but even “superior” to HBV DNA in identifying treatment-naïve patients at 
elevated risk of liver disease. Tada et al. found that HBcrAg was more accurate than HBV DNA 
to predict the development of HCC in a cohort of 1,031 treatment-naïve CHB patients after a 
median follow-up period of 10.7 years without antiviral treatment [35]. The same group also 
reported the superiority of HBcrAg to HBV DNA in predicting the progression to cirrhosis in 
patients without antiviral therapy [36]. Indeed, our study found that HBcrAg was independently 
associated with significant fibrosis and liver inflammation after adjusting for HBV DNA and 
HBeAg, while other HBV markers were not. These results support that the risk stratification 
based on HBcrAg might be more accurate than using HBV DNA to assess eligibility for antiviral 
therapy in CHB patients, although this needs to be further assessed in a longitudinal cohort study.  
 
Compared to the conventional molecular assay, serological assay is better adapted to LMICs with 
limited laboratory capacity because this may be less expensive and simpler to perform. However, 
recent advent of inexpensive automated point-of-care PCR assay, such as GeneXpert, may 
change the landscape of HBV diagnostics in LMICs. Further simplification of HBcrAg assay by 
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developing a rapid diagnostic test with immunochromatographic lateral-flow assay will be 
feasible and possible at a lower cost than the point-of-care HBV DNA PCR. Lowering the limit 
of detection may not be the priority for such a test; for example, a rapid test detecting very high 
HBcrAg levels of 5.3 log U/ml (equivalent to serum HBV DNA levels of 200,000 IU/ml in this 
study) should be enough to identify pregnant women who would benefit most from antiviral 
therapy to prevent mother-to-child transmission [37], given the high diagnostic sensitivity 
(91.4%) and specificity (93.2%) to indicate viral load threshold associated with 
immunoprophylaxis failure [38]. Moreover, the improvement in analytical sensitivity of HBcrAg 
has been recently made (unpublished data), and this may also contribute to the future 
development of rapid HBcrAg test to diagnose lower thresholds equivalent to serum HBV DNA 
levels of 2,000 or 20,000 IU/ml. 
 
As a limitation, HBcrAg was measured in a laboratory in Japan using stored sera. We will soon 
start a field study to validate HBcrAg in a resource-limited African laboratory. Whether HBcrAg 
can be used for identifying African patients in inactive phase who have poor prognosis remains 
unknown. This question will be addressed through a longitudinal follow-up of the PROLIFICA 
cohort in West Africa. Our study was limited to HBV genotypes A and E, and the majority were 
HBeAg-negative with low viral load; a meta-analysis is underway to assess the performance of 
HBcrAg in different HBV genotypes, with a wide range of viral load and HBeAg sero-positivity 
(registered at PROSPERO: CRD42017055440). 
 
Without having simple, affordable, and reliable diagnostic tools to evaluate active HBV 
replication, it is unlikely to reach the WHO’s global elimination goals [39]. HBcrAg, a promising 
alternative to HBV DNA PCR, warrants further validation. 
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Figure Legends 
 
Fig. 1. Flow chart of study participants 
 
Fig. 2. Correlation between HBcrAg & HBV DNA levels, HBsAg-HQ & HBV DNA levels, and 
HBcrAg & HQ-HBsAg levels 
 
Fig. 3. Receiver operating characteristic curves for HBcrAg, HBsAg-HQ, and HBeAg to indicate 
serum HBV DNA levels 
 
Fig. 4. Receiver operating characteristic curves for simplified algorithms to indicate treatment 
eligibility according to the international guidelines 
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Table 1. Characteristics of study participants (n=284) 
Variables Values 
Median age (years) 36 (30-45) 
Male sex, n (%)  188 (66) 
Ever drunk alcohol, n (%) 24 (9) 
Median BMI (kg/m
2
) 22 (19-25) 
Positive HBeAg, n (%) 36 (13) 
HBsAg-HQ, n (%) 0.005 – 1,000 IU/ml  83 (29) 
 1,000 – 10,000 IU/ml 109 (38) 
 ≥ 10,000 IU/ml 92 (32) 
HBcrAg, n (%) Undetectable 132 (47) 
 3.0 – 4.0 log U/ml 75 (26) 
 ≥ 4.0 log U/ml 77 (27) 
HBV DNA, n (%) Undetectable 119 (42) 
 50 – 2,000 IU/ml 99 (35) 
 2,000 – 20,000 IU/ml 21 (7) 
 20,000 – 200,000 IU/ml 10 (4) 
 ≥ 200,000 IU/ml 35 (12) 
HBV genotype, n (%) A 38 (16) 
 E 198 (84) 
Median liver stiffness (kPa) 5.8 (4.5-10.7) 
Liver cirrhosis, n (%) 55 (19) 
Median AST (IU/L) 33 (26-53) 
Median ALT (IU/L) 25 (19-42) 
Median GGT (IU/L) 31 (22-70) 
Median albumin (g/L) 41 (36-44) 
Median total bilirubin (IU/L) 11 (8-18) 
Median platelets (10
9
/L) 180 (130-242) 
Eligible for AASLD treatment criteria (2018), n (%) 59 (21) 
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Eligible for EASL treatment criteria (2017), n (%) 58 (20) 
Eligible for APASL treatment criteria (2015), n (%) 63 (22) 
Eligible for WHO treatment criteria for LMICs (2015), n (%) 140 (49) 
 
Continuous variables are presented as median (interquartile range). 
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Table 2. Performance of serum HBcrAg levels, HBsAg-HQ levels and HBeAg to discriminate clinically important HBV DNA levels  
 HBV DNA levels 
2,000 IU/ml 20,000 IU/ml 200,000 IU/ml 
HBcrAg HBsAg HBeAg HBcrAg HBsAg HBeAg HBcrAg HBsAg HBeAg 
AUROC (95% CI) 0.88 
(0.82-
0.93) 
0.55 
(0.48-
0.62) 
0.73 
(0.66-
0.79) 
0.92 
(0.87-
0.98) 
0.53 
(0.45-
0.61) 
0.79 
(0.71-
0.86) 
0.94 
(0.88-
0.99) 
0.56 
(0.47-
0.66) 
0.83 
(0.75-
0.91) 
P-value (compared to HBcrAg) N/A <0.001 <0.001 N/A <0.001 <0.001 N/A <0.001 0.004 
Cut-off 3.6 log 
U/ml 
3.6 log 
IU/ml 
Positive 4.8 log 
U/ml 
3.6 log 
IU/ml 
Positive 5.3 log 
U/ml 
3.7 log 
IU/ml 
Positive 
Sensitivity (%) 83.3 56.1 47.7 88.9 55.6 61.4 91.4 45.7 70.6 
Specificity (%) 83.9 49.5 97.6 92.9 49.0 96.0 93.2 53.0 94.9 
Positive predictive value (%) 61.1 25.2 86.1 70.2 17.0 75.0 65.3 12.0 66.7 
Negative predictive value (%) 94.3 78.8 85.5 97.8 85.4 92.8 98.7 87.4 95.7 
Positive likelihood ratio 5.2 1.1 19.6 12.5 1.1 15.5 13.4 1.0 13.9 
Negative likelihood ratio 0.2 0.9 0.5 0.1 0.9 0.4 0.1 1.0 0.3 
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Table 3. Virological factors associated with significant liver fibrosis and elevated ALT levels  
1. Association with significant liver fibrosis Significant liver 
fibrosis (%) 
Crude Adjusted* 
OR (95% CI) p-value OR (95% CI) p-value 
HBcrAg 
(log U/ml) 
< 3.6 log U/ml 20% 1.0 <0.001 1.0 <0.001 
3.6 – 5.3 log U/ml 37% 2.3 (1.1-4.7) 2.6 (1.2-5.8) 
≥ 5.3 log U/ml 67% 8.2 (4.1-16.4) 19.7 (4.3-91.1) 
HBsAg-HQ 
(log IU/ml) 
< 3.6 log IU/ml 35% 1.0 0.2   
≥ 3.6 log IU/ml 27% 0.7 (0.4-1.1)  
HBeAg Negative 26% 1.0 <0.001 1.0 0.4 
Positive 61% 4.6 (2.2-9.5) 0.6 (0.2-2.1) 
HBV DNA 
(IU/ml) 
Undetectable 25% 1.0 <0.001 1.0 0.8 
50–2,000 24% 1.0 (0.5-1.8) 1.0 (0.5-2.1) 
2,000–200,000 39% 1.9 (0.8-4.3) 0.7 (0.2-2.0) 
≥200,000 60% 4.5 (2.0-9.8) 0.6 (0.1-2.5) 
HBV genotype E 29% 1.0 1.0   
A 29% 1.0 (0.5-2.2)  
2. Association with elevated ALT (≥40 IU/L) ALT ≥40 IU/L 
(%) 
Crude Adjusted* 
OR (95% CI) p-value OR (95% CI) p-value 
HBcrAg < 3.6 log U/ml 15% 1.0 <0.001 1.0 0.003 
3.6 – 5.3 log U/ml 29% 2.3 (1.0-5.3) 1.9 (0.8-4.7) 
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(log U/ml) ≥ 5.3 log U/ml 73% 15.5 (7.3-32.9) 12.0 (2.8-50.6) 
HBsAg-HQ 
(log IU/ml) 
< 3.6 log IU/ml 31% 1.0 0.1   
≥ 3.6 log IU/ml 23% 0.6 (0.4-1.1)  
HBeAg Negative 20% 1.0 <0.001 1.0 0.7 
Positive 69% 8.7 (4.0-19.0) 0.8 (0.2-3.0) 
HBV DNA 
(IU/ml) 
Undetectable 18% 1.0 <0.001 1.0 0.4 
50–2,000 15% 0.8 (0.4-1.6) 0.8 (0.4-1.8) 
2,000–200,000 48% 4.2 (1.8-10.0) 2.0 (0.7-5.8) 
≥200,000 71% 11.2 (4.7-26.8) 1.7 (0.4-6.9) 
HBV genotype E 26% 1.0 0.9   
A 27% 1.0 (0.5-2.3)  
* The variables significantly associated with the outcomes in the crude analyses (p<0.05) were mutually adjusted.  
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Table 4. Performance of simplified algorithm using HBcrAg, TREAT-B and WHO criteria to 
select patients eligible for antiviral therapy  
 HBcrAg-based algorithm TREAT-B: 
HBeAg 
ALT 
WHO: 
APRI 
ALT 
Model 1*: 
HBcrAg 
HBeAg 
FibroScan 
ALT 
Model 2: 
HBcrAg 
ALT 
Model 3: 
HBcrAg 
alone 
AASLD 2018 
AUROC 
(95% CI) 
0.91 
(0.88-0.95) 
0.90 
(0.85-0.94) 
0.84 
(0.77-0.91) 
0.87 
(0.81-0.92) 
0.73 
(0.68-0.79) 
Cut-off N/A 2 points 3.6 log U/mL 2 points N/A 
Sen (%) 96.6 89.3 83.1 81.8 86.4 
Spe (%) 85.8 74.9 81.8 82.8 60.4 
PPV (%) 64.0 47.6 54.4 55.6 36.4 
NPV (%) 99.0 96.5 94.8 94.5 94.4 
PLR 6.8 3.6 4.6 4.8 2.2 
NLR 0.1 0.1  0.2 0.2 0.2 
EASL 2017 
AUROC 
(95% CI) 
0.91 
(0.88-0.94) 
0.89 
(0.84-0.94) 
0.84 
(0.78-0.91) 
0.87 
(0.81-0.93) 
0.73 
(0.68-0.79) 
Cut-off N/A 2 points 3.6 log U/mL 2 points N/A 
Sen (%) 96.6 89.1 82.8 81.5 86.2 
Spe (%) 85.4 74.5 81.4 82.4 60.2 
PPV (%) 62.9 46.7 53.3 54.3 35.7 
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NPV (%) 99.0 96.5 94.8 94.5 94.4 
PLR 6.6 3.5 4.5 4.6 2.2 
NLR 0.1 0.1 0.2 0.2 0.2 
APASL 2015 
AUROC 
(95% CI) 
0.96 
(0.93-0.98) 
0.96 
(0.94-0.98) 
0.80 
(0.73-0.87) 
0.95 
(0.93-0.98) 
0.80 
(0.75-0.84) 
Cut-off N/A 2 points 3.6 log U/mL 2 points N/A 
Sen (%) 96.8 100 74.6 96.6 95.2 
Spe (%) 94.6 79.4 80.5 87.9 63.8 
PPV (%) 83.6 58.1 52.2 69.1 42.9 
NPV (%) 99.1 100 91.8 98.9 97.9 
PLR 17.8 4.9 3.8 8.0 2.6 
NLR 0.1 0 0.3 0.1 0.1 
* Model 1 is described in details in Supplementary Table 3. 
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